photo #8522566

💉 New Vaccine Offers Hope Against Two of the Deadliest CancersPancreatic and colorectal cancers are notoriously aggressive, with high recurrence rates even after surgery. But a new “off-the-shelf” vaccine — ELI-002 2P — is showing remarkable promise.Developed by researchers across the US, the vaccine targets KRAS gene mutations, which are present in 93% of pancreatic cancers and 50% of colorectal cancers. Using a delivery system that sends the active agent directly to lymph nodes, it trains immune cells to recognize and attack cancer-driving mutations.In a small clinical trial involving 25 patients recovering from these cancers, 84% developed KRAS-specific T cells, and 24% had all detectable tumor traces eliminated. Among those with the strongest immune responses, most remained cancer-free for nearly 20 months — far exceeding typical survival expectations.Because ELI-002 2P is not personalized, it could be deployed more quickly and affordably than custom-made cancer vaccines. Researchers also observed immune activity against other cancer mutations, hinting at broader potential applications.While larger trials are needed, the results suggest ELI-002 2P could become a powerful new tool against some of the hardest-to-treat cancers.RESEARCH PAPER 📄Zev A. Wainberg et al, "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.", Nature Medicine (August 2025)